| 2023 |
Reply |
Lettera |
Go to |
| 2023 |
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis |
Articolo in rivista |
Go to |
| 2022 |
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model |
Articolo in rivista |
Go to |
| 2022 |
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data |
Articolo in rivista |
Go to |
| 2022 |
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices |
Articolo in rivista |
Go to |
| 2022 |
Reply |
Lettera |
Go to |
| 2022 |
Reply |
Lettera |
Go to |
| 2021 |
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort |
Articolo in rivista |
Go to |
| 2021 |
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals |
Articolo in rivista |
Go to |
| 2021 |
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients |
Articolo in rivista |
Go to |
| 2021 |
Systemic therapies for hepatocellular carcinoma: The present and the future |
Articolo in rivista |
Go to |
| 2021 |
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials |
Articolo in rivista |
Go to |
| 2021 |
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use |
Articolo in rivista |
Go to |
| 2021 |
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) |
Articolo in rivista |
Go to |
| 2021 |
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? |
Articolo in rivista |
Go to |
| 2020 |
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma |
Articolo in rivista |
Go to |
| 2020 |
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis |
Articolo in rivista |
Go to |
